Role of peroxisome proliferator-activated receptors in inflammation control

Journal of Biomedicine and Biotechnology

Volumn 2004, Issue 3, 2004, Pages 156-166

  Youssef, Jihan ^a   Badr, Mostafa ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 CHLORO 4 [3 (7 PROPYL 3 TRIFLUOROMETHYLBENZISOXAZOL 6 YLOXY)PROPYLTHIO]PHENYLACETIC ACID; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; CARRAGEENAN; DNA; GW 7647; LEUKOTRIENE B4; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NITRIC OXIDE; PERFLUOROOCTANOIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIRINIXIC ACID; ROSIGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG;

AGING; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CANCER; CELL CYCLE; CYTOKINE PRODUCTION; DEGENERATIVE DISEASE; DIABETES MELLITUS; DNA BINDING; DNA BINDING MOTIF; DRUG DNA BINDING; DRUG MECHANISM; DRUG SPECIFICITY; FERTILITY; HUMAN; INFLAMMATION; LIGAND BINDING; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PAW EDEMA; PROTEIN FAMILY; REVIEW;

EID: 4644269605     PISSN: 11107243     EISSN: None     Source Type: Journal    
DOI: 10.1155/S1110724304308065     Document Type: Review

References (92)

1. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990;347(6294):645- 650.
2. Youssef J, Badr M. Peroxisome proliferator-activated receptors: from orphnage to fame in a decade. Saudi Pharm J. 2002;9:1-13.
3. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev. 1999;20(5):649-688.
4. Willson T, Brown P, Sternbach D, Henke B. The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000;43(4):527-550.
5. Sher T, Yi H, McBride O, Gonzalez F. cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry. 1993;32(21):5598-5604.
6. Mukherjee R, Jow L, Noonan D, McDonnell D. Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators. J Steroid Biochem Mol Biol. 1994;51(3-4):157-166.
7. Greene M, Blumberg B, McBride O, et al. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr. 1995;4(4-5):281-299.
8. Su JL, Simmons C, Wisely B, Ellis B, Winegar D. Monitoring of PPAR alpha protein expression in human tissue by the use of PPAR alpha-specific MAbs. Hybridoma. 1998;17(1):47-53.
9. Mueller E, Sarraf P, Tontonoz P, et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell. 1998;1(3):465-470.
10. Michalik L, Wahli W. Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions. Curr Opin Biotechnol. 1999;10(6):564-570.
11. Cullingford T, Bhakoo K, Peuchen S, Dolphin C, Patel R, Clark J. Distribution of mRNAs encoding the peroxisome proliferator-activated receptor alpha, beta, and gamma and the retinoid X receptor alpha, beta, and gamma in rat central nervous system. J Neurochem. 1998;70(4):1366-1375.
12. Saluja I, Granneman J, Skoff R. PPAR delta agonists stimulate oligodendrocyte differentiation in tissue culture. Glia. 2001;33(3):191-204.
13. Berger J, Leibowitz M, Doebber T, et al. Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem. 1999;274(10):6718-6725.
14. Azab A, Kaplanski J. A reduction of tumor necrosis factor-alpha in paw exudate of lipopolysaccharide treated rats by nimesulide. Life Sci. 2001;68(14): 1667-1675.
15. Salvemini D, Wang ZQ, Wyatt P, et al. Nitric oxide: a key mediator in the early and late phase of carrageenan-induced rat paw inflammation. Br J Pharmacol. 1996;118(4):829-838.
16. Salvemini D, Wang ZQ, Bourdon DM, Stern MK, Currie MG, Manning PT. Evidence of peroxynitrite involvement in the carrageenan-induced rat paw edema. Eur J Pharmacol. 1996;303(3):217-220.
17. Kliewer S, Sundseth S, Jones S, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA. 1997;94(9):4318-4323.
18. Tontonoz P, Singer S, Forman B, et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA. 1997;94(1):237-241.
19. Kersten S, Wahli W. Peroxisome proliferator activated receptor agonists. EXS. 2000;89:141-151.
20. Devchand P, Keller H, Peters J, Vazquez M, Gonzalez F, Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature. 1996;384(6604): 39-43.
21. Forman B, Chen J, Evans R. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA. 1997;94(9):4312-4317.
22. Wolf G. Fatty acids bind directly to and activate peroxisome proliferator-activated receptors alpha and gamma. Nutr Rev. 1998;56(2):61-63.
23. Gustafsson JA. Fatty acids in control of gene expression, Nutr Rev. 1998;56(2)20-21.
24. Youssef J, Badr M. Biology of senescent liver peroxisomes: role in hepatocellular aging and disease. Environ Health Perspect. 1999;107(10):791-797.
25. Masters C, Crane D. On the role of the peroxisome in ontogeny, ageing and degenerative disease. Mech Ageing Dev. 1995;80(2):69-83.
26. Youssef J. Badr M. Peroxisomal alterations in aging and disease. In: Mattson M, ed. Interorganellar Signaling in Age-Related Disease. Amsterdam: Elsevier Press; 2001:1-28.
27. Ricote M, Huang J, Fajas L, et al. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA. 1998;95(13):7614-7619.
28. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol. 1998; 153(1):17-23.
29. Spiegelman BM. PPARgamma in monocytes: less pain, any gain? Cell. 1998;93(2):153-155.
30. Vidal-Puig A, Considine R, Jimenez-Linan M, et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest. 1997;99(10):2416-2422.
31. Lefebvre AM, Laville M, Vega N, et al. Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes. 1998;47(1):98-103.
32. Spiegelman B, Flier J, Adipogenesis and obesity: rounding out the big picture. Cell. 1996;87(3):377-389.
33. Brun R, Tontonoz P, Forman B, et al. Differential activation of adipogenesis by multiple PPAR isoforms. Genes Dev. 1996;10(8):974-984.
34. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell. 1995;83(5):813-819.
35. Lim H, Gupta R, Ma WG, et al. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARδ. Genes Dev. 1999; 13(12):1561-1574.
36. Cattley R, DeLuca J, Elcombe C, et al. Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans? Regul Toxicol Pharmacol. 1998;27(1):47-60.
37. Karam WG, Ghanayem BI. Induction of replicative DNA synthesis and PPAR alpha-dependent gene transcription by Wy-14 643 in primary rat hepatocyte and non-parenchymal cell co-cultures. Carcinogenesis. 1997;18(11):2077-2083.
38. Youssef J, Badr M. Enhanced hepatocarcinogenicity due to agonists of peroxisome proliferator-activated receptors in senescent rats: role of peroxisome proliferation, cell proliferation, and apoptosis, Scientific-WorldJournal. 2002;2:1491-1500.
39. Saez E, Tontonoz P, Nelson M, et al. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med. 1998;4(9):1058-1061.
40. Chao C, Youssef J, Rezaiekhaleigh M, Birnbaum L, Badr M. Senescence-associated decline in hepatic peroxisomal enzyme activities corresponds with diminished levels of retinoid X receptor alpha, but not peroxisome proliferator-activated receptor alpha, Mech Ageing Dev. 2002;123(11):1469-1476.
41. Jakobs BS, Wanders RJ. Conclusive evidence that very-long-chain fatty acids are oxidized exclusively in peroxisomes in human skin fibroblasts. Biochem Biophys Res Commun. 1991;178(3):842-847.
42. Zs-Nagy I. The role of membrane structure and function in cellular aging: a review. Mech Ageing Dev. 1979;9(3-4):237-346.
43. Perichon R, Bourre JM. Aging-related decrease in liver peroxisomal fatty acid oxidation in control and clofibrate-treated mice. A biochemical study and mechanistic approach. Mech Ageing Dev. 1996;87(2):115-126.
44. Roth G, Joseph J, Mason R. Membrane alterations as causes of impaired signal transduction in Alzheimer's disease and aging, Trends Neurosci. 1995;18(5):203-206.
45. Bentley P, Calder I, Elcombe C, Grasso P, Stringer D, Wiegand HJ, Hepatic peroxisome proliferation in rodents and its significance for humans. Food Chem Toxicol. 1993;31(11):857-907.
46. Roberts R, James N, Woodyatt N, Macdonald N, Tugwood J. Evidence for the suppression of apoptosis by the peroxisome proliferator activated receptor alpha (PPAR alpha). Carcinogenesis. 1998;19(1):43-48.
47. Bayly AC, Roberts RA, Dive C. Suppression of liver cell apoptosis in vitro by the non-genotoxic hepatocarcinogen and peroxisome proliferator nafenopin. J Cell Biol. 1994;125(1):197-203.
48. Seed B. PPARgamma and colorectal carcinoma: conflicts in a nuclear family. Nat Med. 1998;4(9):1004-1005.
49. Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med. 1998;4(9):1046-1052.
50. Badawi A, Badr M. Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma (Review). Int J Oncol. 2002;20(6):1109-1122.
51. He TC, Chan T, Vogelstein B, Kinzler K. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell. 1999;99(3):335-345.
52. Berger J, Moller D. The mechanisms of action of PPARs. Annu Rev Med. 2002;53:409-935.
53. Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol. 2001;169(3):453-459.
54. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res. 2000;49(10):497-505.
55. Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature. 1997;387(6633): 620-624.
56. von Schacky C, Kiefl R, Marcus A, Broekman M, Kaminski W. Dietary n-3 fatty acids accelerate catabolism of leukotriene B4 in human granulocytes. Biochim Biophys Acta. 1993;1166(1):20-24.
57. Couve A, Koenig C, Santos M. Induction of peroxisomal enzymes and a 64-kDa peptide in cultured mouse macrophages treated with clofibrate. Exp Cell Res. 1992;202(2):541-544.
58. Poynter M, Daynes R. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem. 1998;273(49):32833-32841.
59. Hill MR, Clarke S, Rodgers K, et al. Effect of peroxisome proliferator-activated receptor alpha activators on tumor necrosis factor expression in mice during endotoxemia. Infect Immun. 1999;67(7):3488-3493.
60. Taylor B, Dadia N, Yang C, Krishnan S, Badr M. Peroxisome proliferator-activated receptor agonists inhibit inflammatory edema and hyperalgesia. Inflammation. 2002;26(3):121-127.
61. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391(6662):82-86.
62. Ricote M, Li A, Willson T, Kelly CJ, Glass C. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391(6662):79-82.
63. Cuzzocrea S, Wayman N, Mazzon E, et al. The cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J(2) attenuates the development of acute and chronic inflammation. Mol Pharmacol. 2002;61(5):997-1007.
64. Ricote M, Huang JT, Welch JS, Glass CK. The peroxisome proliferator-activated receptor (PPARgamma) as a regulator of monocyte/macrophage function. J Leukoc Biol. 1999;66(5):733-739.
65. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998;93(2):241-252.
66. Thieringer R, Fenyk-Melody JE, Le Grand CB, et al. Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo. J Immunol. 2000;164(2):1046-1054.
67. Clark R. The role of PPARs in inflammation and immunity. J Leukoc Biol. 2002;71(3):388-400.
68. Stamler J. Redox signaling: nitrosylation and related target interactions of nitric oxide. Cell. 1994; 78(6):931-936.
69. Heneka M, Klockgether T, Feinstein D. Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci. 2000;20(18):6862-6867.
70. Reilly C, Oates J, Cook J, Morrow J, Halushka P, Gilkeson G. Inhibition of mesangial cell nitric oxide in MRL/lpr mice by prostaglandin J2 and proliferator activation receptor-gamma agonists. J Immunol. 2000;164(3):1498- 1504.
71. Combs C, Johnson D, Karlo J, Cannady S, Landreth G. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci. 2000;20(2):558-567.
72. Kaufmann W, Andreasson K, Isakson P, Worley P. Cyclooxygenases and the central nervous system. Prostaglandins. 1997;54(3):601-624.
73. Su C, Wen X, Bailey S, et al. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest. 1999;104(4):383-389.
74. Kawahito Y, Kondo M, Tsubouchi Y, et al. 15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest. 2000;106(2):189-197.
75. Niino M, Iwabuchi K, Kikuchi S, et al. Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma. J Neuroimmunol. 2001;116(1):40-48.
76. Vinegar R, Schreiber W, Hugo R. Biphasic development of carrageenin edema in rats. J Pharmacol Exp Ther. 1969;166(1):96-103.
77. Cunard R, Ricote M, DiCampli D, et al. Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J Immunol. 2002;168(6):2795-2802.
78. Hattori Y, Hattori S, Kasai K. Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells. Hypertension. 1999;33(4):943-948.
79. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med. 2001;7(1):48-52.
80. Petrova TV, Akama KT, Van Eldik LJ. Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of inducible nitric-oxide synthase by 15-deoxy-Delta12,14-prostaglandin J2. Proc Natl Acad Sci USA. 1999;96(8):4668-4673.
81. Camp H, Li O, Wise S, et al. Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. Diabetes. 2000;49(4):539-347.
82. Cuzzocrea S, Costantino G, Mazzon E, Caputi AP. Beneficial effects of raxofelast (IRFI 016), a new hydrophilic vitamin E-like antioxidant, in carrageenan-induced pleurisy. Br J Pharmacol. 1999; 126(2):407-414.
83. Salvemini D, Wang ZQ, Stern MK, Currie MG, Misko TP. Peroxynitrite decomposition catalysts: therapeutics for peroxynitrite-mediated pathology. Proc Natl Acad Sci USA. 1998;95(5):2659-2663.
84. Cuzzocrea S, Riley DP, Caputi AP, Salvemini D. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev. 2001;53(1):135-159.
85. Cuzzocrea S, Zingarelli B, Costantino G, Caputi AP. Beneficial effects of Mn(III)tetrakis (4-benzoic acid) porphyrin (MnTBAP), a superoxide dismutase mimetic, in carrageenan-induced pleurisy. Free Radic Biol Med. 1999;26(1-2):25-33.
86. Tracey WR, Nakane M, Kuk J, et al. The nitric oxide synthase inhibitor, L-NG-monomethylarginine, reduces carrageenan-induced pleurisy in the rat. J Pharmacol Exp Ther. 1995;273(3):1295-1299.
87. Wei XQ, Charles IG, Smith A, et al. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature. 1995;375(6530):408-411.
88. Kaur H, Halliwell B. Evidence for nitric oxide-mediated oxidative damage in chronic inflammation. Nitrotyrosine in serum and synovial fluid from rheumatoid patients. FEBS Lett. 1994;350(1):9-12.
89. Miller MJ, Thompson JH, Zhang XJ, et al. Role of inducible nitric oxide synthase expression and peroxynitrite formation in guinea pig ileitis. Gastroenterology. 1995;109(5):1475-1483.
90. Chamulitrat W, Skrepnik NV, Spitzer JJ. Endotoxin-induced oxidative stress in the rat small intestine: role of nitric oxide. Shock. 1996;5(3):217-222.
91. Rachmilewitz D, Stamler JS, Karmeli F, et al. Peroxynitrite-induced rat colitis - a new model of colonic inflammation. Gastroenterology. 1993;105(6): 1681-1688.
92. Seo HG, Takata I, Nakamura M, et al. Induction of nitric oxide synthase and concomitant suppression of superoxide dismutases in experimental colitis in rats. Arch Biochem Biophys. 1995;324(1):41-47.